A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1

Selective free fatty acid receptor 1 (FFAR1)/GPR40 agonist fasiglifam (TAK-875), an antidiabetic drug under phase 3 development, potentiates insulin secretion in a glucose-dependent manner by activating FFAR1 expressed in pancreatic β cells. Although fasiglifam significantly improved glycemic contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Yabuki, Chiori, Komatsu, Hidetoshi, Tsujihata, Yoshiyuki, Maeda, Risa, Ito, Ryo, Matsuda-Nagasumi, Kae, Sakuma, Kensuke, Miyawaki, Kazumasa, Kikuchi, Naoya, Takeuchi, Koji, Habata, Yugo, Mori, Masaaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794927/
https://www.ncbi.nlm.nih.gov/pubmed/24130766
http://dx.doi.org/10.1371/journal.pone.0076280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794927/
https://www.ncbi.nlm.nih.gov/pubmed/24130766
http://dx.doi.org/10.1371/journal.pone.0076280

Ejemplares similares